PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Cytokine and Growth Factor Reviews

Volumn 15, Issue 4, 2004, Pages 229-235

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; PDGF; Restenosis; Tyrphostins

Indexed keywords

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 370; AGL 2033; AGL 2043; CT 52923; IMATINIB; NANOPARTICLE; PACLITAXEL; PHENYLBENZIMIDAZOLE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PYRIDINYLQUINOLINE; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RAPAMYCIN; RECEPTOR BLOCKING AGENT; RPR 101511A; SUNITINIB; UNCLASSIFIED DRUG; VANADIUM PENTOXIDE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COATED PARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DRUG ELUTING STENT; DRUG FORMULATION; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GRAFT REJECTION; HUMAN; IC 50; LIVER FIBROSIS; LUNG FIBROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; RESTENOSIS; REVIEW;

EID: 2942630916     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2004.03.010     Document Type: Article

References (48)

1. Pietras K., Sjoblom T., Rubin K., Heldin C.H., Ostman A. PDGF receptors as cancer drug targets. Cancer Cell. 3:2003;439-443
2. Rutherford R.B., Ross R. Platelet factors stimulate fibroblasts and smooth muscle cells quiescent in plasma serum to proliferate. J. Cell Biol. 69:1976;196-203
3. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N. Engl. J. Med. 295:1976;369-377
4. O'Brien K.P., Seroussi E., Dal Cin P., Sciot R., Mandahl N., Fletcher J.A., et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFβ gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer. 23:1998;187-193
5. Shimizu A., O'Brien K.P., Sjoblom T., Pietras K., Buchdunger E., Collins V.P., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:1999;3719-3723
6. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316
7. George D. Targeting PDGF receptors in cancer - rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. 532:2003;141-151
8. Bilder G.E., Krawiec J.A., McVety K., Gazit A., Gilon C., Lyall R., et al. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260:1991;C721-C730
9. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 100:2002;1088-1091
10. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2001;2929-2934
11. Bryckaert M.C., Eldor A., Fontenay M., Gazit A., Osherov N., Gilon C., et al. Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp. Cell Res. 199:1992;255-261
12. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C.H., et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114
13. Gazit A., App H., McMahon G., Chen J., Levitzki A., Bohmer F.D. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J. Med. Chem. 39:1996;2170-2177
14. Gazit A., Yee K., Uecker A., Bohmer F.D., Sjoblom T., Ostman A., et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg. Med. Chem. 11:2003;2007-2018
15. Kilic T., Alberta J.A., Zdunek P.R., Acar M., Iannarelli P., O'Reilly T., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:2000;5143-5150
16. Matsuno K., Ichimura M., Nakajima T., Tahara K., Fujiwara S., Kase H., et al. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J. Med. Chem. 45:2002;3057-3066
17. Dolle R.E., Dunn J.A., Bobko M., Singh B., Kuster J.E., Baizman E., et al. 5, 7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 37:1994;2627-2629
18. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2:2003;471-478
19. Palmer B.D., Smaill J.B., Boyd M., Boschelli D.H., Doherty A.M., Hamby J.M., et al. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J. Med. Chem. 41:1998;5457-5465
20. Pandey A., Volkots D.L., Seroogy J.M., Rose J.W., Yu J.C., Lambing J.L., et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. 45:2002;3772-3793
21. Yu J.C., Lokker N.A., Hollenbach S., Apatira M., Li J., Betz A., et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J. Pharmacol. Exp. Ther. 298:2001;1172-1178
22. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36:2003;462-469
23. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82:1999;231-239
24. Kovalenko M., Ronnstrand L., Heldin C.H., Loubtchenkov M., Gazit A., Levitzki A., et al. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 36:1997;6260-6269
25. Kenagy R.D., Hart C.E., Stetler-Stevenson W.G., Clowes A.W. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation. 96:1997;3555-3560
26. Lindner V., Reidy M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;3739-3743
27. Neschis D.G., Safford S.D., Hanna A.K., Fox J.C., Golden M.A. Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J. Vasc. Surg. 27:1998;126-134
28. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129-1132
29. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1788
30. Golomb G., Fishbein I., Banai S., Mishaly D., Moscovitz D., Gertz S.D., et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis. 125:1996;171-182
31. Banai S., Wolf Y., Golomb G., Pearle A., Waltenberger J., Fishbein I., et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 97:1998;1960-1969
32. Banai S, Chorny M, Gertz SD, Gazit A, Gao J, Fishbein, et al. Local delivery of nanoencapsulated tyrphostin inhibits stenosis in balloon-injured rat carotid and stented porcine coronary arteries, 2004, in press.
33. Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043). Reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Circulation, 2004, in press.
34. Bilder G., Wentz T., Leadley R., Amin D., Byan L., O'Conner B., et al. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation. 99:1999;3292-3299
35. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104:2001;1188-1193
36. Indolfi C., Avvedimento E.V., Rapacciuolo A., Di Lorenzo E., Esposito G., Stabile E., et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat. Med. 1:1995;541-545
37. Park S.J., Shim W.H., Ho D.S., Raizner A.E., Park S.W., Hong M.K., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348:2003;1537-1545
38. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350:2004;221-231
39. Hosenpud J.D., Hershberger R.E., Pantely G.A., Norman D.J., Hovaguimian H., Cobanoglu A., et al. Late infection in cardiac allograft recipients: profiles, incidence, and outcome. J. Heart Lung Transplant. 10:1991;380-386
40. Behrendt D., Ganz P., Fang J.C. Cardiac allograft vasculopathy. Curr. Opin. Cardiol. 15:2000;422-429
41. Karck M., Meliss R., Hestermann M., Mengel M., Pethig K., Levitzki A., et al. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation. 74:2002;1335-1341
42. Iwamoto H., Nakamuta M., Tada S., Sugimoto R., Enjoji M., Nawata H. Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. J. Lab. Clin. Med. 135:2000;406-412
43. Lindroos P.M., Wang Y.Z., Rice A.B., Bonner J.C. Regulation of PDGFR-alpha in rat pulmonary myofibroblasts by staurosporine. Am. J. Physiol. Lung Cell Mol. Physiol. 280:2001;L354-L362
44. Rice A.B., Moomaw C.R., Morgan D.L., Bonner J.C. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am. J. Pathol. 155:1999;213-221
45. Zheng Y., Ikuno Y., Ohj M., Kusaka S., Jiang R., Cekic O., et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn. J. Ophthalmol. 47:2003;158-165
46. Abe J., Zhou W., Taguchi J., Takuwa N., Miki K., Okazaki H., et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198:1994;16-24
47. Chang M.W., Barr E., Lu M.M., Barton K., Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268
48. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:2000;139-145